My research looks at the role that antitrust and intellectual property law can play in promoting invention while reducing risk, with a particular focus on the pharmaceutical industry. I have been published in the Antitrust Law Journal, the BMJ, JAMA Internal Medicine, and JAMA Oncology, among other outlets.
In ongoing work, I am studying how intellectual property law and export controls can be used to reduce catastrophic risks, especially from novel and engineered pathogens. Before starting law school, I worked for several years at Bloomberg News in Boston covering the biotechnology industry.
Feel free to reach out at doni.bloomfield@jhu.edu with any questions.
Publications
Extending Drug Monopolies by Patenting Safe Drug Use
Doni Bloomfield, Bryan S. Walsh, Aaron S. Kesselheim
JAMA Internal Medicine, vol. 182(3), 2022, pp. 245-246
Doni Bloomfield, Elvira D’Andrea, Sarosh Nagar, Aaron S. Kesselheim
JAMA Oncology, vol. 8(4), 2022, pp. 537-545
Improving the Quality of US Drug Patents Through International Awareness
Doni Bloomfield, Zhigang Lu, Aaron S. Kesselheim
British Medical Journal, vol. 377, 2022
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.
William B. Feldman, Doni Bloomfield, Reed F. Beall, Aaron S. Kesselheim
Health Affairs, vol. 41(6), 2022
A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs
Bryan S. Walsh, Doni Bloomfield, Aaron S. Kesselheim
JAMA, vol. 326(14), 2021, pp. 1371-1372
Consumers and Citizens: The Future of the Consumer Welfare Standard in Global Merger Review
Jesse Solomon, Gregory S. Morrison, Doni Bloomfield
Antitrust Law Journal, vol. 84, 2021, pp. 701-743
